129 related articles for article (PubMed ID: 32671807)
1. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis.
Iacovelli R; Ciccarese C; Facchini G; Milella M; Urbano F; Basso U; De Giorgi U; Sabbatini R; Santini D; Berardi R; Santoni M; Bracarda S; Massari F; Masini C; De Tursi M; Ricotta R; Buti S; Zustovich F; Sepe P; Rossetti S; Maruzzo M; Cortesi E; Tortora G; Procopio G
Target Oncol; 2020 Aug; 15(4):495-501. PubMed ID: 32671807
[TBL] [Abstract][Full Text] [Related]
2. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9).
Damassi A; Cremante M; Signori A; Rebuzzi SE; Fornarini G; Giudice GC; Maruzzo M; Procopio G; Sorarù M; Di Napoli M; Fratino L; Santini D; Grillone F; Ballestrin M; Dionese M; Nasso C; Catalano F; Murianni V; Rescigno P; Anpalakhan S; Banna GL; Basso U; Buti S
Clin Genitourin Cancer; 2024 Apr; 22(2):126-133.e2. PubMed ID: 37932204
[TBL] [Abstract][Full Text] [Related]
4. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma.
Bruchbacher A; Franke J; Alimohammadi A; Laukhtina E; Fajkovic H; Schmidinger M
Clin Genitourin Cancer; 2024 Apr; 22(2):98-108. PubMed ID: 37926597
[TBL] [Abstract][Full Text] [Related]
5. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
Hahn AW; Surasi DS; Viscuse PV; Bathala TK; Wiele AJ; Campbell MT; Zurita AJ; Shah AY; Jonasch E; Gao J; Goswami S; Alhalabi O; Rao P; Sircar K; Tannir NM; Msaouel P
Oncologist; 2024 May; 29(5):392-399. PubMed ID: 38035767
[TBL] [Abstract][Full Text] [Related]
6. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
Ishihara H; Omae K; Nemoto Y; Ishiyama R; Tachibana H; Nishimura K; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T
Int J Clin Oncol; 2024 Apr; 29(4):473-480. PubMed ID: 38345708
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis.
Schmidt E; Lister J; Neumann M; Wiecek W; Fu S; Vataire AL; Sostar J; Huang S; Marteau F
Target Oncol; 2018 Apr; 13(2):205-216. PubMed ID: 29492762
[TBL] [Abstract][Full Text] [Related]
8. First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy.
Yanagisawa T; Kawada T; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Chlosta M; Quhal F; Pradere B; Karakiewicz PI; Mori K; Kimura T; Shariat SF; Schmidinger M
BJU Int; 2024 Apr; ():. PubMed ID: 38659099
[TBL] [Abstract][Full Text] [Related]
9. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Liu Y; Shabto JM; Carthon BC; Hitron EE; Russler GA; Caulfield S; Kissick HT; Harris WB; Kucuk O; Master VA; Bilen MA
Oncologist; 2020 Mar; 25(3):e484-e491. PubMed ID: 32162798
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial.
Fitzgerald KN; Lee CH; Voss MH; Carlo MI; Knezevic A; Peralta L; Chen Y; Lefkowitz RA; Shah NJ; Owens CN; McHugh DJ; Aggen DH; Laccetti AL; Kotecha RR; Feldman DR; Motzer RJ
Eur Urol; 2024 May; ():. PubMed ID: 38782695
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases.
Xu J; Higgins MJ; Tolaney SM; Come SE; Smith MR; Fornier M; Mahmood U; Baselga J; Yeap BY; Chabner BA; Isakoff SJ
Oncologist; 2020 Aug; 25(8):652-660. PubMed ID: 32463152
[TBL] [Abstract][Full Text] [Related]
12. Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
Blanchet B; Xu-Vuilard A; Jouinot A; Puisset F; Combarel D; Huillard O; Le Louedec F; Thomas F; Teixeira M; Flippot R; Mourey L; Albiges L; Pudlarz T; Joly C; Tournigand C; Chauvin J; Puszkiel A; Chatelut E; Decleves X; Vidal M; Goldwasser F; Oudard S; Medioni J; Vano YA
Br J Cancer; 2024 Apr; 130(6):961-969. PubMed ID: 38272963
[TBL] [Abstract][Full Text] [Related]
13. Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Powles T;
Ann Oncol; 2021 Mar; 32(3):422-423. PubMed ID: 33271289
[No Abstract] [Full Text] [Related]
14. Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma.
Lue HW; Derrick DS; Rao S; Van Gaest A; Cheng L; Podolak J; Lawson S; Xue C; Garg D; White R; Ryan CW; Drake JM; Ritz A; Heiser LM; Thomas GV
Cell Rep Med; 2021 May; 2(5):100267. PubMed ID: 34095877
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients-Real-World Experience in a Single-Center Retrospective Study and Narrative Review.
Domański P; Piętak M; Staneta S; Fortuniak W; Kruczyk B; Kobiernik A; Bakuła P; Mydlak A; Demkow T; Sikora-Kupis B; Dumnicka P; Kucharz J
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541124
[No Abstract] [Full Text] [Related]
16. Contemporary Treatment of Metastatic Renal Cell Carcinoma.
Stukalin I; Alimohamed N; Heng DY
Oncol Rev; 2016 Apr; 10(1):295. PubMed ID: 27471582
[TBL] [Abstract][Full Text] [Related]
17. Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis).
Graham J; Ghosh S; Breau RH; Wood L; Tanguay S; Bosse D; Lalani AK; Bhindi B; Heng D; Finelli A; Fallah-Rad N; Castonguay V; Basappa NS; Soulières D; Pouliot F; Kollmannsberger C; Bjarnason GA
Clin Genitourin Cancer; 2024 Feb; ():102060. PubMed ID: 38521648
[TBL] [Abstract][Full Text] [Related]
18. Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma.
Sharma A; Elias R; Christie A; Williams NS; Pedrosa I; Bjarnason GA; Brugarolas J
Kidney Cancer; 2022; 6(1):69-79. PubMed ID: 36743424
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib.
Scirocchi F; Napoletano C; Pace A; Rahimi Koshkaki H; Di Filippo A; Zizzari IG; Nuti M; Rughetti A
Front Oncol; 2021; 11():755433. PubMed ID: 34745989
[TBL] [Abstract][Full Text] [Related]
20. Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis.
Iacovelli R; Ciccarese C; Facchini G; Milella M; Urbano F; Basso U; De Giorgi U; Sabbatini R; Santini D; Berardi R; Santoni M; Bracarda S; Massari F; Masini C; De Tursi M; Ricotta R; Buti S; Zustovich F; Sepe P; Rossetti S; Maruzzo M; Cortesi E; Tortora G; Procopio G
Target Oncol; 2020 Oct; 15(5):691. PubMed ID: 32857328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
